Forgot Password?
Return to Course Listing

CME: Metastatic Melanoma: Updates from ASCO 2017

Activity Description / Statement of Need:

In this online CME self-learning program:

 

Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners.  ASCO 2017 is no exception.  Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting. 

 

Metastatic Melanoma

 

Melanoma is a tumor of the melanocytes whose tissue of origin is primarily the skin, although it may also develop occasionally in the: gastrointestinal, genitourinary, or respiratory tracts; ocular or mucosal tissue; or meninges. It is subcategorized into superficial spreading melanoma (70% of cases), nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. Risk factors include a positive personal or family history of melanoma, genetic predisposition, and exposure to ultraviolet light. Diagnosis is made by excisional, incisional, or punch skin biopsy while imaging or indirect ophthalmoscopy may be employed to diagnose uveal or choroidal melanoma. The seventh most common cancer in the U.S., it has an annual incidence of over 76,000.

 

 

Agenda:

 

Faculty member introduction, disclosures

Major findings from ASCO 2017 related to Metastatic Melanoma, including clinical trial data  relevant to both community and health-system practice and recognized barriers to implementing those findings in practice

Application: patient cases

Summary, conclusion, and best practice recap

 

 

 

 

 

Target Audience:

Oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.


This program is supported by educational grants from Amgen.


Release Date: September 19, 2017 -- Expiration Date: September 19, 2019

Faculty: Kim Margolin, MD

Agenda

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize the most impactful findings presented at ASCO 2017 relating to Metastatic Melanoma and apply them to patient cases, taking into account any relevant barriers to care.
  • Additional objectives to be dictated by clinical content

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosure:  Kim Margolin, MD has received financial compensation from participation at advisory boards and/or research grants from Pfizer, Amgen, Lowrance, Merck, BMS, Checkmate, and Altor Bioscience.

 

Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.

 

Commercial Support Disclosure: This program is supported by educational grants from Amgen.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly- Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

Basal Cell Carcinoma (BCC): Therapeutic Updates, Best Practices, and the Role of Personalized Patient Care